KCT0006668尚未招募未知
Variability of dynamic contrast-enhanced MRI in the pituitary adenoma: Prospective comparison between gadobutrol and meglumine gadoterate usage
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 20?(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •Adults who are planned to undergo pituitary MRI including DCE-MRI for the suspicion of the pituitary tumor and agree to be included in this prospective study
排除标准
- •Under age 19 years old, pregant woman, those who do not agree to be included in this study, those who have history of side effect for the gadolinium-based MRI contrast agent including allergic reaction, those who have severe kidney or heart problem, those who have intractable hypokalemia, those who cannot be injected with gadolinium-based MRI contrast-agent from various reasons
研究者
相似试验
进行中（未招募）
不适用
STARBEAM-X: Assessing blood flow in brain tumors using MRI before and after targeted radiation treatmentCancerISRCTN62305334ewcastle upon Tyne Hospitals NHS Foundation Trust40
进行中（未招募）
不适用
Differences in dynamic contrast-enhanced (DCE) MRI measurements using Magnevist (Gd-DTPA) and Vas-ovist in patients with untreated squamous cell cervical carcinoma. - NDntreated squamous cell cervical carcinoma(SCCC).MedDRA version: 9.1Level: HLTClassification code 10029109Term: Cervix neoplasmsEUCTR2008-002958-37-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
2 期
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-alpha in patients with advanced renal cell carcinomaAdvanced or metastatic renal cell carcinomaMalignant neoplasm of kidney, except renal pelvisCancerISRCTN08193901East and North Hertfordshire NHS Trust (UK)30
已完成
不适用
Dynamic Contrast-Enhanced Magnetic Resonance Imaging Study for Biochemocal Failures after Radical ProstatectomyProstate cancerJPRN-UMIN000009823The University of Tokyo Hospital50
已完成
不适用
the utility of dynamic contrase-enhanced MRI for advanced and metastatic breast cancer administerd with bevacizumabbreast cancerJPRN-UMIN000021677kyoto prefectural university of medicine20